Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Hsu, Jing Fang ^a   Chou, Tzu Chieh ^b   Lu, Jonathan ^c   Chen, Shu Hua ^c   Chen, Fang Yu ^a   Chen, Ching Chu ^a   Chen, Jeffrey L ^d   Elayda, MacArthur ^c   Ballantyne, Christie M ^e   Shayani, Steven ^f,g   Chen, Chu Huang ^a,c,e,h  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TEXAS HEART INSTITUTE   (United States)

^d University of California San Diego ^*  (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g New York Cardiology Associates   (United States)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN;

ADULT; ANIMAL CELL; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; NONHUMAN; RISK FACTOR; SMOKING; WAIST CIRCUMFERENCE; WAIST TO HEIGHT RATIO; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84929940268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107340     Document Type: Article

References (47)

1. CDC (2011) Heart disease and stroke prevention, addressing the nation's leading killers. Chronic Disease Prevention and Health Promotion. United States.
2. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M (2006) Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27: 1610-1619.
3. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, et al. (2012) Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308: 788-795.
4. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, et al. (2009) Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. preventive services task force. Ann Intern Med 151: 496-507.
5. Gupta S, Gudapati R, Gaurav K, Bhise M (2013) Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocrinol Metab 17: 806-814.
6. Kashyap ML (1997) Cholesterol and atherosclerosis: A contemporary perspective. Ann Acad Med Singapore 26: 517-523.
7. Cziraky MJ, Watson KE, Talbert RL (2008) Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14: S3-28; quiz S30-21.
8. Avogaro P, Bon GB, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8: 79-87.
9. Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J (2004) Electronegative lowdensity lipoprotein. Curr Opin Lipidol 15: 329-335.
10. Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, et al. (1996) A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 16: 773-783.
11. Ziouzenkova O, Asatryan L, Sahady D, Orasanu G, Perrey S, et al. (2003) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 278: 39874-39881.
12. Benitez S, Sanchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, et al. (2003) Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108: 92-96.
13. Sánchez-Quesada JL, Estruch M, Benítez S, Ordóñ ez-Llanos J (2012) Electronegative LDL: A useful biomarker of cardiovascular risk? Clinical Lipidology 7: 345-359.
14. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, et al. (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107: 2102-2108.
15. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, et al. (2003) Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol 23: 1083-1090.
16. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, et al. (2008) Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 49: 33-47.
17. Chan HC, Ke LY, Chu CS, Lee AS, Shen MY, et al. (2013) Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation. Blood 122: 3632-3641.
18. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, et al. (2013) Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: A novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res 99: 137-145.
19. Ke LY, Engler DA, Lu J, Matsunami RK, Chan HC, et al. (2011) Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure Appl Chem 83: 1731-1740.
20. Lu J, Yang JH, Burns AR, Chen HH, Tang D, et al. (2009) Mediation of electronegative low-density lipoprotein signaling by LOX-1: A possible mechanism of endothelial apoptosis. Circ Res 104: 619-627.
21. Tang D, Lu J, Walterscheid JP, Chen H-H, Engler DA, et al. (2008) Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 49: 33-47.
22. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, et al. (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28: 385-390.
23. Mihic M, Modi P (2008) Metabolic syndrome-risk factors for atherosclerosis and diabetes. Curr Diabetes Rev 4: 122-128.
24. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, et al. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49: 403-414.
25. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, et al. (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56: 1113-1132.
26. Lee AS, Chen WY, Chan HC, Hsu JF, Shen MY, et al. (2014) Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. Cardiovasc Diabetol 13: 64-73.
27. Chu CS, Wang YC, Lu LS, Walton B, Yilmaz HR, et al. (2013) Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One 8: E70533.
28. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
29. Aviram M (1983) Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med 30: 111-118.
30. Chen CH, Cartwright J Jr, Li Z, Lou S, Nguyen HH, et al. (1997) Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 17: 1303-1312.
31. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117: 743-753.
32. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS (2009) Predicting the 30-year risk of cardiovascular disease: The framingham heart study. Circulation 119: 3078-3084.
33. Jonckheere AR (1954) A Distribution-Free k-Sample Test Against Ordered Alternatives. Biometrika 41: 133-145.
34. WHO (2009) Global health risks: Mortality and burden of disease attributable to selected major risks. World Health Organization.
35. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716.
36. De Castellarnau C, Sanchez-Quesada JL, Benitez S, Rosa R, Caveda L, et al. (2000) Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 20: 2281-2287.
37. Abe Y, Fornage M, Yang CY, Bui-Thanh NA, Wise V, et al. (2007) L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis 192: 56-66.
38. Lee AS, Wang GJ, Chan HC, Chen FY, Chang CM, et al. (2012) Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines. Apoptosis 17: 1009-1018.
39. Benitez S, Bancells C, Ordonez-Llanos J, Sanchez-Quesada JL (2007) Proinflammatory action of LDL(-) on mononuclear cells is counteracted by increased IL10 production. Biochim Biophys Acta 1771: 613-622.
40. Guevara NV, Chen KH, Chan L (2001) Apoptosis in atherosclerosis: Pathological and pharmacological implications. Pharmacol Res 44: 59-71.
41. Choy JC, Granville DJ, Hunt DW, McManus BM (2001) Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33: 1673-1690.
42. Fraley AE, Tsimikas S (2006) Clinical applications of circulating oxidized lowdensity lipoprotein biomarkers in cardiovascular disease. Current Opinion in Lipidology 17: 502-509.
43. Sanchez-Quesada JL, Camacho M, Anton R, Benitez S, Vila L, et al. (2003) Electronegative LDL of FH subjects: Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166: 261-270.
44. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2004) The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007.
45. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, et al. (2004) Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174: 343-347.
46. Pohjantahti-Maaroos H, Palomaki A, Kankkunen P, Laitinen R, Husgafvel S, et al. (2010) Circulating oxidized low-density lipoproteins and arterial elasticity: Comparison between men with metabolic syndrome and physically active counterparts. Cardiovasc Diabetol 9: 41.
47. Pohjantahti-Maaroos H, Palomaki A, Kankkunen P, Husgafvel S, Knuth T, et al. (2012) Arterial elasticity and oxidized LDL among men with metabolic syndrome and different 10-year cardiovascular risk estimated by FINRISK and SCORE models. Ann Med 44: 503-512.